Seroatlas · Human Serome Atlas

TRAPPC9

Trafficking protein particle complex subunit 9

Also known as: IKBKBBP, KIAA1882, MRT13, NIBP, T1, TPPC9_HUMAN, TRS120

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96Q05
Gene: TRAPPC9
Ensembl: ENSG00000167632
Chromosome: 8
Canonical length: 1148 aa
Protein class: Disease related genes, Human disease related genes, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Golgi apparatus,Vesicles

OverviewNCBI Gene

This gene encodes a protein that likely plays a role in NF-kappa-B signaling. Mutations in this gene have been associated with autosomal-recessive cognitive disability. Alternatively spliced transcript variants have been described.[provided by RefSeq, Feb 2010]

Canonical amino-acid sequenceUniProt

1148 residues, UniProt reviewed canonical sequence.

>Q96Q05|TRAPPC9
     1  MSVPDYMQCA EDHQTLLVVV QPVGIVSEEN FFRIYKRICS VSQISVRDSQ RVLYIRYRHH
    61  YPPENNEWGD FQTHRKVVGL ITITDCFSAK DWPQTFEKFH VQKEIYGSTL YDSRLFVFGL
   121  QGEIVEQPRT DVAFYPNYED CQTVEKRIED FIESLFIVLE SKRLDRATDK SGDKIPLLCV
   181  PFEKKDFVGL DTDSRHYKKR CQGRMRKHVG DLCLQAGMLQ DSLVHYHMSV ELLRSVNDFL
   241  WLGAALEGLC SASVIYHYPG GTGGKSGARR FQGSTLPAEA ANRHRPGAQE VLIDPGALTT
   301  NGINPDTSTE IGRAKNCLSP EDIIDKYKEA ISYYSKYKNA GVIELEACIK AVRVLAIQKR
   361  SMEASEFLQN AVYINLRQLS EEEKIQRYSI LSELYELIGF HRKSAFFKRV AAMQCVAPSI
   421  AEPGWRACYK LLLETLPGYS LSLDPKDFSR GTHRGWAAVQ MRLLHELVYA SRRMGNPALS
   481  VRHLSFLLQT MLDFLSDQEK KDVAQSLENY TSKCPGTMEP IALPGGLTLP PVPFTKLPIV
   541  RHVKLLNLPA SLRPHKMKSL LGQNVSTKSP FIYSPIIAHN RGEERNKKID FQWVQGDVCE
   601  VQLMVYNPMP FELRVENMGL LTSGVEFESL PAALSLPAES GLYPVTLVGV PQTTGTITVN
   661  GYHTTVFGVF SDCLLDNLPG IKTSGSTVEV IPALPRLQIS TSLPRSAHSL QPSSGDEIST
   721  NVSVQLYNGE SQQLIIKLEN IGMEPLEKLE VTSKVLTTKE KLYGDFLSWK LEETLAQFPL
   781  QPGKVATFTI NIKVKLDFSC QENLLQDLSD DGISVSGFPL SSPFRQVVRP RVEGKPVNPP
   841  ESNKAGDYSH VKTLEAVLNF KYSGGPGHTE GYYRNLSLGL HVEVEPSVFF TRVSTLPATS
   901  TRQCHLLLDV FNSTEHELTV STRSSEALIL HAGECQRMAI QVDKFNFESF PESPGEKGQF
   961  ANPKQLEEER REARGLEIHS KLGICWRIPS LKRSGEASVE GLLNQLVLEH LQLAPLQWDV
  1021  LVDGQPCDRE AVAACQVGDP VRLEVRLTNR SPRSVGPFAL TVVPFQDHQN GVHNYDLHDT
  1081  VSFVGSSTFY LDAVQPSGQS ACLGALLFLY TGDFFLHIRF HEDSTSKELP PSWFCLPSVH
  1141  VCALEAQA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRAPPC9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 31 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 31 nTPM
parathyroid gland: 26 nTPM
pituitary gland: 21 nTPM
cerebral cortex: 18 nTPM
tongue: 17 nTPM
cerebellum: 16 nTPM

Single-cell type

lactotrophs: 886 nCPM
somatotrophs: 745 nCPM
thyrotrophs: 703 nCPM
gonadotrophs: 617 nCPM
corticotrophs: 546 nCPM
renal connecting tubule cells: 518 nCPM

Immune cell

basophil: 15 nTPM
neutrophil: 5 nTPM
NK-cell: 4.9 nTPM
MAIT T-cell: 4.6 nTPM
naive B-cell: 4.5 nTPM
gdT-cell: 4.2 nTPM

Brain region

midbrain: 40 nTPM
pons: 38 nTPM
medulla oblongata: 37 nTPM
white matter: 36 nTPM
choroid plexus: 36 nTPM
thalamus: 34 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TRAPPC9.

Disease | AllUniProt

Conditions TRAPPC9 is implicated in, by any mechanism.

Intellectual developmental disorder, autosomal recessive 13 (MRT13) MIM:613192

Disease | GeneticClinVar

82 pathogenic / likely-pathogenic of 1,039 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Intellectual disability, autosomal recessive 13
Inborn genetic diseases
Abnormality of the nervous system
TRAPPC9-related disorder
Schizophrenia

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.73
gnomAD pLI: 0
gnomAD missense Z: 1.48
DepMap mean gene effect: -0.17
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 14% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

Trs120/TRAPPC9
Trs120/TRAPPC9, N-terminal domain
Trs120/TRAPPC9, TPR region
Trs120/TRAPPC9, first Ig-like domain
Trs120/TRAPPC9, third Ig-like domain
Trs120/TRAPPC9, fourth Ig-like domain
Trs120/TRAPPC9, N-terminal domain
Trs120/TRAPPC9 TPR
Trs120/TRAPPC9, first Ig-like domain
Trs120/TRAPPC9, second Ig-like domain
Trs120/TRAPPC9, third Ig-like domain
Trs120/TRAPPC9, fourth Ig-like domain

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRAPPC9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRAPPC9 as an antibody target. Whether an autoantibody or antibody against TRAPPC9 could matter depends on whether native TRAPPC9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRAPPC9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRAPPC9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...